EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting STAT3 in systemic lupus erythematosus and lupus nephritis: mechanisms, therapeutic advances, and structure-informed perspectives

Fangyu Yi, Xiao Tu, Ruxi Jin, Jiayue Zhou, Yayu Li, Haiyang Liao, Wanyue Xu, Yuan Yuan, Mengting Wu, Peng Bi, Jiazhen Yin

Frontiers in Pharmacology · 04.06.2026 · 17

DOI: 10.3389/fphar.2026.1854754 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 04.06.2026. Verfasst von Fangyu Yi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Hangzhou Clinical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China. Die Arbeit nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This review summarizes the mechanistic and therapeutic relevance of Signal Transducer and Activator of Transcription 3 (STAT3) in systemic lupus erythematosus (SLE) and lupus nephritis (LN), with an emphasis on how structural information can inform drug development. STAT3 integrates cytokine- and growth factor-driven JAK-STAT signaling, supports pathological T cell differentiation, B cell activation, and renal inflammation, and has therefore emerged as a potential therapeutic node in lupus. Current pharmacological evidence includes traditional Chinese medicine-derived compounds, repurposed or conventional immunomodulators, and clinically advancing JAK-STAT pathway inhibitors; however, most agents act through upstream or indirect modulation rather than direct STAT3 targeting. Structure-informed analyses of candidate compounds further suggest differential druggability across STAT3 domains, with the CCD and SH2 domain providing plausible binding surfaces, whereas the DBD remains comparatively inaccessible. Together, current evidence supports STAT3 as a mechanistically important and therapeutically tractable axis in SLE and LN, while highlighting the need for biochemical, cellular, and in vivo validation of domain-selective inhibitors, dual-domain engagement strategies, and degrader-based approaches.

Schlagwörter

Stichwörter der Autor:innen

STAT3domain-specific inhibitionlupus nephritissmall molecule therapeuticsstructure-informed perspectivessystemic lupus erythematosus

Autor:innen und Institutionen

  • Hangzhou Clinical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
  • Hangzhou Hospital of Traditional Chinese Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
  • Department of Nephrology (Key Laboratory of Kidney Disease Prevention and Control Technology), Hangzhou Hospital of Traditional Chinese Medicine, Hangzhou, Zhejiang, China.

Zitieren

APA

Yi, F., Tu, X., Jin, R., Zhou, J., Li, Y., Liao, H., Xu, W., Yuan, Y., Wu, M., Bi, P., & Yin, J. (2026). Targeting STAT3 in systemic lupus erythematosus and lupus nephritis: mechanisms, therapeutic advances, and structure-informed perspectives. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1854754

Vancouver

Yi F, Tu X, Jin R, Zhou J, Li Y, Liao H, et al. Targeting STAT3 in systemic lupus erythematosus and lupus nephritis: mechanisms, therapeutic advances, and structure-informed perspectives. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1854754

BibTeX
@article{Yi2026,
  author = {Yi, Fangyu and Tu, Xiao and Jin, Ruxi and Zhou, Jiayue and Li, Yayu and Liao, Haiyang and Xu, Wanyue and Yuan, Yuan and Wu, Mengting and Bi, Peng and Yin, Jiazhen},
  title = {Targeting STAT3 in systemic lupus erythematosus and lupus nephritis: mechanisms, therapeutic advances, and structure-informed perspectives},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1854754}
}
Kostenlos starten →